AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT04752163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV or PO
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Given PO
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04752163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Given PO
Study NCT05361824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Injection
Description: dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
Study NCT05361824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
Study NCT05366023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BUD1
Description: 10 hours of bottom-up driven computerized cognitive training designed to improve processing speed and divided attention
Study NCT05366023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BUD2
Description: 10 hours of bottom-up driven computerized cognitive training designed to improve divided attention
Study NCT05366023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TDD1
Description: 10 hours of top-down driven computerized cognitive training designed to improve multiple object tracking
Study NCT05366023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TDD2
Description: 10 hours of top-down driven computerized cognitive training designed to improve executive function
Study NCT05366023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CSA10
Description: 10 hours of computerized games
Study NCT05366023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CSA20
Description: 20 hours of computerized games
Study NCT05366023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CSA30
Description: 30 hours of computerized games
Study NCT05366023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CSA40
Description: 40 hours of computerized games
Study NCT05660460 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometry
Description: The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
Study NCT06182943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture combined with surrounding acupuncture
Description: electroacupuncture combined with surrounding acupuncture
Study NCT06182943 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: sham electroacupuncture
Study NCT06182943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ice compress combined with brake rest
Description: ice compress combined with brake rest
Study NCT06160232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (high dose)
Description: Psilocybin-assisted therapy
Study NCT06160232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active placebo (low dose of psilocybin)
Description: Placebo-assisted therapy
Study NCT05783206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIR 19 ®
Description: MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs.
Study NCT05783206 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)
Study NCT05222828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbocaine Injectable Product
Description: One injection per patient
Study NCT03796507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
Study NCT06036277 — intervention group
Intervention type: OTHER
Intervention: General data
Description: General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight
Study NCT06036277 — intervention group
Intervention type: OTHER
Intervention: Other data
Description: Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.
Study NCT05356416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Ischemic compression technique is a massage technique that consists of moderate compression, typically applied with the fingers, to the MTrP. Application of this technique to an MTrP results in a positive effect on pain-pressure threshold.~Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds.
Study NCT05356416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.~Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses.
Study NCT03867032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training
Description: Training with psychophysical tests (amplitude modulation detection on single electrodes) for improving speech recognition
Study NCT05611632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-cancer early detection test (Galleri test)
Description: Blood collection and multi cancer early detection testing with return of positive test results.
Study NCT05806437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sideremil vita cp
Description: assunzione per 30 giorni dell'integratore
Study NCT05806437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sideremil vita cp
Description: assunzione per 30 giorni dell'integratore
Study NCT04912778 — intervention group
Intervention type: OTHER
Intervention: Filling in an online survey
Description: Patients are asked to fill in an online survey regarding functional status, quality of life and symptoms of central sensitisation.
Study NCT04711785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent exercise program
Description: The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week.
Study NCT04508166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
Study NCT04508166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
Study NCT04508166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma-Hydroxybutyrate
Description: Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
Study NCT04508166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
Study NCT04508166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
Study NCT04508166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
Study NCT04508166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Model Trauma Film
Description: Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
Study NCT04508166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Model Trauma Film
Description: Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
Study NCT04508166 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Model Trauma Film
Description: Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
Study NCT06292962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcutaneous vagal nerve stimulation (tVNS)
Description: The device is used stimulate the vagus nerve
Study NCT06251063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based psychoeducational resource
Description: The website will incorporate animations/illustrations to enhance comprehension, patient stories, and video-based expert explanations.~The materials will address the following content areas:~* Provide families with data demonstrating how prevalent social relationship struggles are for children with CDH.~* Describe specific social challenges that commonly affect children with CDH.~* Explain the impact that medications typically prescribed for CDH may have on social relationship health.~* Help families advocate for their child's social needs at school.~* Support children and their families in decision-making about appropriate disclosure with peers at school and in extracurricular settings.~* Offer strategies to support families in raising the issue of social relationship health with the child's sleep physician.~* Provide a list of programming which offers children both structured and unstructured opportunities for social engagement
Study NCT06292962 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham device that does not stimulate the vagus nerve
Study NCT04907526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mononuclear cells
Description: Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.
Study NCT06101654 — intervention group
Intervention type: DEVICE
Intervention: Pulse oximeter
Description: Devices (4) were placed on the finger and the fingertip of both index fingers. Blood samples were taken at each stable level of oxygenation.
Study NCT06544304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA
Description: PMMA 30%
Study NCT05147077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group.
Study NCT05147077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group.
Study NCT05518435 — intervention group
Intervention type: OTHER
Intervention: None, observational study
Description: The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
Study NCT06547580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based PFMT
Description: Under the supervision of an experienced physiotherapist, group-based pelvic floor muscle training was applied for 12 weeks, 2 sessions per week, 30-45 minutes each session.
Study NCT06547580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized PFMT
Description: Under the supervision of an experienced physiotherapist, individualized pelvic floor muscle training was performed using the Emg Biofeedback device, 2 sessions a week, 30-45 minutes each session, in 12 weeks.
Study NCT04605510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Cervical Joint Mobilization
Description: It will be applied to the cervical spine, whose dysfunction is detected as a result of the evaluation. The participant will be in the prone position and Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied for 3 sets, 30 seconds, to the segment to be treated.
Study NCT03935269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cereset Research Wearable
Description: CRW is a stress-relaxation device where participants listen to sounds that help to balance brain rhythms. Participants will be asked to come to an office for 5 days over 1-2 weeks, on your their schedule. Sessions will take approximately one (1) hour to complete.
Study NCT03935269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress management therapy
Description: Undergo Cereset research office intervention
Study NCT03935269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT03935269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study NCT06546267 — intervention group
Intervention type: RADIATION
Intervention: Image Guided Radiotherapy
Description: Patients treated with IGRT for Prostate cancer will be evaluated
Study NCT06546267 — intervention group
Intervention type: RADIATION
Intervention: Intensity Modulated Radiotherapy
Description: Patients treated with IMRT for Prostate cancer will be evaluated
Study NCT06546267 — intervention group
Intervention type: RADIATION
Intervention: Stereotactic Body Radiotherapy
Description: Patients treated with SBRT for Prostate cancer will be evaluated
Study NCT05105698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)
Description: Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)
Study NCT05105698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)
Description: Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)
Study NCT05123625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduce surgical procedures
Description: In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
Study NCT05337956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block catheter
Description: All ESP blocks will be performed in lateral position after general anesthesia induction. ESPB will be performed under ultrasonographic guidance using a linear 6- to 10-MHz ultrasound probe. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T6-10 spinous process. The erector spinae muscles will be identiﬁed superﬁcial to the tip of the transverse process. A 21-gauge 10-cm needle will be inserted using an in-plane superior-to-inferior approach or an out of plane approach. The tip of the needle will be placed into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be conﬁrmed by visible ﬂuid spread lifting erector spinae muscle oﬀ the bony shadow of the transverse process on Ultrasonographic imaging. A total of 10-15 ml of 0.2% ropivacaine will be injected each side. A catheter will then be placed leaving 5 cm in place.
Study NCT04916574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
Description: Concentration of active substance on nasal mucosal surface in time
Study NCT05332431 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Patient with different types of migraine and age and sex matched control group will be subjected to OCT in the ophthalmology department in Assiut University Hospital to assess the following parameters:~Optic nerve head parameters and retinal nerve fibre layer thickness and measuring macular thickness in migraine patients will be measured using optical coherence tomography (OCT) after pupillary dilatation. Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°) will be measured by OCT.
Study NCT04908397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: supplement provided twice a day for 2 weeks
Study NCT04731389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based cognitive-behavioral therapy
Description: Composed of 4 modules: the first module will address psychoeducation on dermatillomania, self-monitoring of symptoms and habit reversal techniques; the second module works with anxiety coping techniques (diaphragmatic breathing and muscle relaxation); module 3 addresses cognitive correction techniques, such as stopping thinking, analyzing evidence, reassigning severity and responsibilities; the last module reviews the techniques learned and addresses techniques for preventing symptom relapse. The modules will be applied by the patient in an online format, each module lasts an average of 30 minutes. The platform will send notice by email through automation tools, SMS or message by application to patients to remind them to complete 1 module per week.